Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label follow-on study of VIAject in type 2 diabetes mellitus
2007-006085-15Phase 3Completed
- Sponsor
- Biodel Inc.
- Start
- Feb 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of VIAject in type 2 diabetes mellitus (T2DM), sponsored by Biodel Inc. Primary endpoint: Frequency of hypoglycemic events. Started Feb 2009; status: completed.
02
Drugs
VIAject
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2007-006085-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006085-15.